Shreya will offer the product through its sales force of more than 1,000 people and will implement a continuing medical education program to introduce the product to endocrinologists, diabetologists and physicians in India and expects that the product will eventually be available in more than 2,500 pharmacies in the country.
Generex Oral-lyn is approved in India for the treatment of adults and children with Type 1 and Type 2 diabetes and will be marketed and sold under the brand name ‘Oral-Recosulin’.
Oral-Recosulin, a flexible, familiar and pain-free alternative to prandial injections of insulin, is expected to be widely available for retail purchase in India before the end of November 2008.
Sujit Kumar Singh, chairman and managing director of Shreya, said: “Early intervention with insulin therapy could delay the onset and progression of diabetes and its numerous complications. We look forward to our collaboration with Generex to revolutionize the treatment of diabetes in India.”